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Abstract: Importance In science and medical research, extreme and dichotomous conclusions may be
drawn based on whether the P value falls above or below the threshold. The fragility index (ie, the
minimum number of changes from nonevents to events resulting in loss of statistical significance) captures
the vulnerability of statistics in trials with binary outcomes. There are a growing number of clinical
trials of immune checkpoint inhibitors (ICIs), as well as expanding eligibility for patients to receive
them. The robustness of survival outcomes in randomized clinical trials (RCTs) should be evaluated
using the fragility index extended to time-to-event data. Objective To calculate the fragility of survival
data in RCTs evaluating ICIs. Design, Setting, and Participants In this cross-sectional study, data on
phase 3 prospective RCTs investigating ICIs included in PubMed from inception until January 1, 2020,
were extracted. Two- or three-group studies reporting results for overall survival were eligible for the
survival-inferred fragility index (SIFI) calculation, which is the minimum number of reassignments of
the best survivors from the interventional group to the control group resulting in loss of significance
(defined as P < .05 by log-rank test). For nonsignificant results, a negative SIFI was calculated by
reversing the direction of reassignment (from the control group to the interventional group). Main
Outcomes and Measures Survival-inferred fragility index. Results A total of 45 phase 3 prospective RCTs
(4 of which had 3 groups, for a total of 49 groups) were identified, of which 6 (13%) investigated anti-
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agents, 25 (56%) investigated anti-programmed
cell death 1 (PD-1) agents, 12 (27%) investigated anti-programmed cell death 1 ligand 1 agents, and
3 (7%) investigated the combination of anti-CTLA-4 and anti-PD-1 agents. The median SIFI was 5
(interquartile range, -4 to 12) for the intention-to-treat analysis; for these trials, the SIFI was 1% or less
of the total sample size in 17 of 49 populations (35%). In 25 of the 49 intention-to-treat populations
(51%), the SIFI was less than the number of censored patients in the intervention group shortly after
randomization (defined as <5% of the follow-up time). Conclusions and Relevance This study suggests
that many phase 3 RCTs evaluating ICI therapies have a low SIFI for overall survival, resulting in
uncertainty regarding their potential clinical benefit. Although not a definitive solution for the problems
arising from dichotomization, SIFI provides an additional means of assessing and communicating the
strength of statistical conclusions.
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Abstract
IMPORTANCE In science andmedical research, extreme and dichotomous conclusions may be
drawn based on whether the P value falls above or below the threshold. The fragility index (ie, the
minimum number of changes from nonevents to events resulting in loss of statistical significance)
captures the vulnerability of statistics in trials with binary outcomes. There are a growing number of
clinical trials of immune checkpoint inhibitors (ICIs), as well as expanding eligibility for patients to
receive them. The robustness of survival outcomes in randomized clinical trials (RCTs) should be
evaluated using the fragility index extended to time-to-event data.
OBJECTIVE To calculate the fragility of survival data in RCTs evaluating ICIs.
DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, data on phase 3 prospective
RCTs investigating ICIs included in PubMed from inception until January 1, 2020, were extracted.
Two- or three-group studies reporting results for overall survival were eligible for the survival-
inferred fragility index (SIFI) calculation, which is theminimum number of reassignments of the best
survivors from the interventional group to the control group resulting in loss of significance (defined
as P < .05 by log-rank test). For nonsignificant results, a negative SIFI was calculated by reversing the
direction of reassignment (from the control group to the interventional group).
MAINOUTCOMESANDMEASURES Survival-inferred fragility index.
RESULTS A total of 45 phase 3 prospective RCTs (4 of which had 3 groups, for a total of 49 groups)
were identified, of which 6 (13%) investigated anti–cytotoxic T-lymphocyte–associated protein 4
(CTLA-4) agents, 25 (56%) investigated anti–programmed cell death 1 (PD-1) agents, 12 (27%)
investigated anti–programmed cell death 1 ligand 1 agents, and 3 (7%) investigated the combination
of anti–CTLA-4 and anti–PD-1 agents. The median SIFI was 5 (interquartile range, –4 to 12) for the
intention-to-treat analysis; for these trials, the SIFI was 1% or less of the total sample size in 17 of 49
populations (35%). In 25 of the 49 intention-to-treat populations (51%), the SIFI was less than the
number of censored patients in the intervention group shortly after randomization (defined as <5%
of the follow-up time).
CONCLUSIONS ANDRELEVANCE This study suggests that many phase 3 RCTs evaluating ICI
therapies have a low SIFI for overall survival, resulting in uncertainty regarding their potential clinical
benefit. Although not a definitive solution for the problems arising from dichotomization, SIFI
provides an additional means of assessing and communicating the strength of statistical conclusions.
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Key Points
Question How stable are the
conclusions of phase 3 randomized
clinical trials of immune checkpoint
inhibitors in oncology?
Findings This cross-sectional study of
45 randomized clinical trials calculated
the survival-inferred fragility index and
found that many oncologic trials
assessing immune checkpoint inhibitors
have a low survival-inferred fragility
index, often less than a small fraction of
the sample size and less than the
number of patients censored soon after
randomization.
Meaning These results challenge the
robustness of many phase 3 randomized
clinical trials of immune checkpoint
inhibitors in oncology and address the
uncertainty regarding their potential
clinical benefit.
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Introduction
Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte–associated protein 4 (CTLA-4)
or programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) have revolutionized
cancer treatment and led to their approval as first-line therapies, either alone or in combination with
chemotherapy, for many solid tumors and hematologic malignant neoplasms.1However, the clinical
benefit associated with ICIs cannot be generalized into a single category, as the therapeutic
effectiveness varies widely across different cancer indications.2-7 The number of active clinical trials
of ICIs is growing rapidly, along with an increased pace of accelerated approvals by the US Food and
Drug Administration (FDA).8,9 The eligibility criteria for ICI therapy are dynamic, and results of
postmarketing studies often lead to label revisions, with more changes expected to follow.10Despite
the popularity of ICIs and the expanding eligibility for expensive and potentially toxic treatments, the
percentage of eligible patients who benefit from ICIs is decreasing.10,11 This gap between ICI eligibility
and clinical benefit is concerning and is not fully understood.
Since the introduction of the P value almost a century ago, reliance on a fixed cutoff serving as
the gatekeeper for establishing significance in clinical trials has caused controversy.12,13 Statistically
significant differences in outcomes using an arbitrary threshold (P < .05) may not be clinically
relevant, especially when the estimated outcome does not offer substantial clinical benefit.14,15 The
fragility of statistical inference can be signified by the ease with which a significant P value (P < .05)
crosses over the significance threshold (P > .05).16,17 Johnson et al18 introduced a method to
compute the fragility for survival analysis by iteratively adding artificial patients to the experimental
group with events at the mean exposure time of all individuals until significance is lost. Using this
method, one study has recently shown that the fragility index of time-to-event data can be used to
estimate the level of confidence of positive results reported in randomized clinical trials (RCTs)
leading to FDA approval of anticancer drugs.19However, this approach that simulates average
“virtual” patients might inflate the fragility estimate as patients at the extreme, who contribute the
most to the survival curves, are disregarded.Many possible ways could be formulated to estimate the
fragility of survival data. Therefore, we aimed to define a simple and intuitive fragility measure for
survival analysis, based on real-life conditions, that captures the vulnerability of the data. Hence, we
define the survival-inferred fragility index (SIFI) as the minimum number of reassignments of the
best survivors (defined as the patients with the longest follow-up time, regardless of having an event
or being censored; the worst survivors were defined as the patients with the earliest events) from
the experimental group to the control group resulting in loss of significance (Figure 1). The purpose
of this study is to evaluate the fragility of phase 3 RCTs comparing ICIs with control or standard
treatments in a time-aware context.
Methods
StudyDesign
The cross-sectional study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.20We searched PubMed from inception until January 1,
2020, for phase 3 RCTs of ICIs (anti–CTLA-4, anti–PD-1, and anti–PD-L1) compared with standard
treatment in solid and hematologic malignant neoplasms. Key words for the literature search included
randomised, randomized, phase 3, phase III, ipilimumab, nivolumab, pembrolizumab, cemiplimab,
durvalumab, avelumab, and atezolizumab. For the fragility analysis, we included 2- or 3-group studies
that reported overall survival as a primary or secondary outcome.We excluded retrospective studies,
pooled studies, and post hoc subgroup analyses. When duplicate publications for the same trial were
identified, we included themost updated publication.We abstracted information on trial design and the
number of enrolled patients in the study. According to institutional reviewboard policy, ethical approval
is not required because no human data were included and publicly available information was used.
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Data Extraction
Overall survival data from 45 trials were extracted from Kaplan-Meier curves in themain text using
DigitizeIt software (DigitizeIt) and the method by Wei and Royston21 using Stata, version 13.0



































































































































HR = 0.76 (95% CI, 0.56-1.04)
P = .09
A, Original reconstructed survival curve. B, Second iteration of the survival curve. C,
Third iteration of the survival curve. The SIFI in this example is 2, which is the iterative
reassignment of the best survivors (designated by circles at the end of the survival
curves) from the experimental group to the control group, until positive significance is
lost (defined as α = .05 using log-rank test). HR indicates hazard ratio.
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(StataCorp). This reverse-engineering strategy enabled us to reproduce survival time and censoring
status at the individual patient level with minor differences between reconstructed and published
data.19We excluded publications of trials with raster images in which data extraction could not be
performed directly. We separated the populations into 2 cohorts—the intention-to-treat (ITT)
populations, which also includedmodified ITT populations, and subgroup populations.
Statistical Analysis
The SIFI was calculated from Kaplan-Meier curves by the iterative redesignation of the best survivors
from the experimental group to the control group until positive significance (defined as P < .05
obtained with a 2-sided log-rank test) was lost. Negative SIFI was calculated similarly, but the
direction was opposite—redesignation of the best survivors from the control group to the
experimental group. In addition to the default SIFI application (flipping the best survivor from the
intervention group to the control group), we defined 3 alternative approaches: flipping the worst
survivor from the experimental group to the control group, cloning the best survivor in the
experimental group into the control group, and cloning the worst survivor in the control group to the
experimental group. P values were calculated with the 2-sided unstratified log-rank test. The
follow-up time distribution was calculated using the prodlim package in R (R Foundation for
Statistical Computing). All other analyses were performed in R, version 3.5.0. The code used to
calculate SIFI is available online.22
To provide a reference for the ranges of SIFI for various parameters of survival data, we
generated synthetic survival data with the survsim package in R.23 The “simple.surv.sim” function
was used with theWeibull distribution for both the time to event and the time to censoring. The
cohort size was set to range from 100 to 1200 individuals in intervals of 100 (with a 1:1 allocation).
The ancillary parameter for the events was set to 1.5, and the ancillary parameter for the censoring
was set to 2, 4, 6, 8, or 10. The covariate for the effect size was set to all values between −1 and 0.2 in
increments of 0.05. The β0 parameter for the event distribution was set to 2.0, and the β0 for the
censoring distribution was set to 2.01.
Results
For the period until January 1, 2020, we identified 45 phase 3 RCTs (4 of which had 3 groups, for a
total of 49 groups)2-7,24-62 evaluating ICI therapies that met the inclusion criteria for survival fragility
analysis. All except 2 multiple myeloma trials (4%)2,47 investigated solid tumors. Six trials (13%)
investigated an anti–CTLA-4 agent (ipilimumab),6,24-28 25 trials (56%) investigated anti–PD-1 agents
(nivolumab and pembrolizumab),2,3,29-51 12 trials (27%) investigated anti–PD-L1 agents
(atezolizumab, avelumab, and durvalumab),5,7,52-61 and 3 trials (7%) investigated the combination of
anti–CTLA-4 and anti–PD-1 agents (ipilimumab and nivolumab).4,36,62We could not calculate the SIFI
for 2 trials (CA184-002 and CA184-043)63,64 because of an incompatible graphical format of the
Kaplan-Meier plots. Themedian sample size for the eligible trials was 559 (interquartile range [IQR],
418-727). The SIFI was calculated for an additional 36 subgroups (eg, PD-L1, 1%) in 15 trials with a
median sample size of 362 (IQR, 217-486).4,7,28,31,36,37,41,46,51-53,56,57,59,62
Thirty-four of the 49 reconstructed overall survival curves in the ITT population (69%), which
includes themodified ITT population, and 26 of the 36 subgroup populations (72%) were significant
(P < .05) (Table 1).2-7,24-62 Themedian SIFI for ITT populations was 5 (IQR, –4 to 12) (ie, a median of
5 patients [among best survivors] reassigned to the control group was required to shift the results
from significant to nonsignificant). The median SIFI for subgroup populations was 3.5 (IQR, 1-6.3)
(eTable in the Supplement). In comparison, the fragility estimate for survival data by Johnson et al18
is unable to estimate fragility for nonsignificant results (negative fragility) and depicts higher values,
with a median of 29 (IQR, 0-51) for the ITT populations and 29 (IQR, 0-43) for the subgroup
populations. The absolute SIFI was less than 1% of the sample size in 17 (35%) of the 49 ITT
populations and 10 (28%) of the 36 subgroup populations. Furthermore, in 25 (51%) of the 49 ITT
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Table 1. SIFI of Overall Survival Calculated for 45 Phase 3 Trials Evaluating Immune Checkpoint Inhibitors in the Intention-to-Treat Populations
Intervention Control Tumor type Clinical trial Year Sample size HR P valuea SIFIb
Anti–CTLA-4
Ipilimumab + dacarbazine Dacarbazine Melanoma CA184-02424 2015 502 0.72 .001 7
Ipilimumab Placebo Melanoma CA184-02925 2016 951 0.72 .002 20
Ipilimumab Placebo PC CA184-0956 2017 602 1.11 .47 −21
Ipilimumab + etoposide + platinum Etoposide + platinum SCLC CA184-15626c 2016 954 0.94 .44 −7
Ipilimumab + paclitaxel +
carboplatin
Paclitaxel + carboplatin Squamous NSCLC CA184-10427c 2017 749 0.91 .17 −3
Ipilimumab, 10 mg/kg Ipilimumab, 3 mg/kg Melanoma CA184-16928 2017 727 0.84 .04 1
Anti–PD-1
Nivolumab Docetaxel Squamous NSCLC CheckMate 01729 2015 272 0.59 .0003 8
Nivolumab Docetaxel Nonsquamous NSCLC CheckMate 05730 2015 582 0.73 .004 5
Nivolumab Everolimus RCC CheckMate 02531 2019 821 0.74 .003 10
Nivolumab Platinum NSCLC CheckMate 02632d 2017 423 1.02 .77 −16
Nivolumab Placebo GC or GEJC ATTRACTION-233 2017 493 0.63 <.0001 10
Nivolumab Dacarbazine or carboplatin + paclitaxel Melanoma CheckMate 03734 2018 405 0.95 .59 −9
Nivolumab Dacarbazine Melanoma CheckMate 06635 2019 418 0.46 <.0001 30
Nivolumab Ipilimumab Melanoma CheckMate 06736 2018 631 0.65 <.0001 23
Nivolumab Methotrexate, docetaxel, or cetuximab HNSCC CheckMate 14137 2018 361 0.68 .001 5
Nivolumab Paclitaxel or docetaxel ESCC ATTRACTION-338 2019 419 0.77 .015 2
Nivolumab Docetaxel NSCLC CheckMate 07839 2019 504 0.68 .003 5
Pembrolizumab Platinum NSCLC KEYNOTE-02440e 2016 305 0.60 .01 6
Pembrolizumab
Every 2 wk Ipilimumab Melanoma KEYNOTE-0063 2017 557 0.68 .001 15
Every 3 wk Ipilimumab Melanoma KEYNOTE-0063 2017 555 0.68 .001 14
Pembrolizumab Methotrexate, docetaxel, or cetuximab HNSCC KEYNOTE-04041 2018 495 0.8 .02 3
Pembrolizumab Paclitaxel GC or GEJC KEYNOTE-06142 2018 395 0.82 .06 −1
Pembrolizumab + pemetrexed +
platinum
Pemetrexed + platinum Nonsquamous NSCLC KEYNOTE-18943 2018 616 0.49 <.0001 40
Pembrolizumab + carboplatin +
paclitaxel or nab-paclitaxel
Carboplatin + paclitaxel or nab-paclitaxel Squamous NSCLC KEYNOTE-40744 2018 559 0.64 .002 10
Pembrolizumab Paclitaxel, docetaxel, or vinflunine UC KEYNOTE-04545 2019 542 0.70 .0005 9
Pembrolizumab Cetuximab + platinum + fluorouracil HNSCC KEYNOTE-04846 2019 601 0.83 .02 2
Pembrolizumab + platinum +
fluorouracil
Cetuximab + platinum + fluorouracil HNSCC KEYNOTE-04846 2019 559 0.77 .005 5
Pembrolizumab + pomalidomide +
dexamethasone
Pomalidomide + dexamethasone MM KEYNOTE-18347 2019 249 1.61 .14 −47
Pembrolizumab + lenalidomide +
dexamethasone
Lenalidomide + dexamethasone MM KEYNOTE-1852 2019 301 2.06 .06 −79
Pembrolizumab Placebo HCC KEYNOTE-24048 2020 413 0.78 .04 1
Pembrolizumab + axitinib Sunitinib RCC KEYNOTE-42649 2019 861 0.53 .0003 40
Pembrolizumab epacadostat Pembrolizumab Melanoma KEYNOTE-25250 2019 706 1.13 .44 −43
























































































































































Table 1. SIFI of Overall Survival Calculated for 45 Phase 3 Trials Evaluating Immune Checkpoint Inhibitors in the Intention-to-Treat Populations (continued)
Intervention Control Tumor type Clinical trial Year Sample size HR P valuea SIFIb
Anti–PD-L1
Atezolizumab Paclitaxel, docetaxel, or vinflunine UC IMvigor21152 2018 931 0.85 .02 3
Atezolizumab Docetaxel NSCLC OAK53f 2018 850 0.85 .0003 12
Atezolizumab + bevacizumab +
carboplatin + paclitaxel
Bevacizumab + carboplatin + paclitaxel Nonsquamous NSCLC IMpower15054g 2018 696 0.78 .02 4
Atezolizumab + carboplatin +
etoposide
Carboplatin + etoposide SCLC IMpower13355 2018 403 0.70 .01 3
Atezolizumab + carboplatin +
nab-paclitaxel
Carboplatin + nab-paclitaxel Nonsquamous NSCLC IMpower13056 2019 723 0.79 .03 2
Atezolizumab + bevacizumab Sunitinib RCC IMmotion15157 2019 915 0.93 .71 −23
Atezolizumab + nab-paclitaxel Nab-paclitaxel BRCA IMpassion1307 2020 846 0.86 .13 −4
Atezolizumab Regorafenib CRC IMblaze3705 2019 180 1.19 .35 −12
Atezolizumab + cobimetinib Regorafenib CRC IMblaze3705 2019 273 1.0 .8 −9
Avelumab Paclitaxel or irinotecan GC or GEJC JAVELIN Gastric 30058 2018 371 1.1 .47 −13
Avelumab Docetaxel NSCLC JAVELIN Lung 20059d 2018 529 0.9 .36 −6
Durvalumab Placebo NSCLC PACIFIC60 2018 713 0.68 .001 15
Durvalumab + platinum + etoposide Platinum + etoposide SCLC CASPIAN61 2019 537 0.73 .003 6
Anti–PD-1 + anti–CTLA-4
Ipilimumab + nivolumab Ipilimumab Melanoma CheckMate 06736 2018 629 0.54 <.0001 38
Ipilimumab + nivolumab Sunitinib RCC CheckMate 2144 2019 1096 0.71 .003 18
Ipilimumab + nivolumab Platinum doublet NSCLC CheckMate 22762 2019 1166 0.73 <.0001 24
Abbreviations: BRCA, breast cancer; CRC, colorectal cancer; CTLA-4, cytotoxic T-lymphocyte–associated protein
4; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HCC,
hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; MM, multiple
myeloma; NSCLC, non–small cell lung carcinoma; PC, prostate cancer; PD-1, programmed cell death 1; PD-L1,
programmed cell death 1 ligand 1; RCC, renal cell carcinoma; SCLC, small cell lung carcinoma; SIFI, survival-inferred
fragility index; UC, urothelial carcinoma.
a Calculated using 2-sided unstratified log-rank test.
b Survival-inferred fragility index associated with the calculated P value (α = .05).
c Modified intention-to-treat populations.
d PD-L1  1%.
e PD-L1  50%.
f Intention-to-treat populations (n = 850).
























































































































































populations and 16 (44%) of the 36 subgroup populations, the SIFI was less than the number of
patients censored in the interventional group during only the first ventile (1/20th) of the follow-up
time (eFigure 1 in the Supplement).
A comparison between positive SIFI levels in different tumor types among ITT populations
(Figure 2) showed that non–small cell lung carcinoma, renal cell carcinoma, andmelanoma had the
highest values and that hepatocellular carcinoma, head and neck squamous cell carcinoma, and small
cell lung carcinoma had the lowest values. Examining the association between SIFI and P values (in
logarithmic scale) revealed a high correlation in ITT populations (R = 0.70; P < 1 × 10−7) and subgroup
populations (R = 0.82; P < 1 × 10−9). However, the level of SIFI was not explained entirely by the
variation in P values. For example, despite having relatively similar P values, hazard ratios, and sample
sizes, the SIFI was 2-fold higher in KEYNOTE-02440 compared with IMpower133,55 and in
ATTRACTION-233 compared with CheckMate 06736monotherapy (Table 1,2-7,24-62 Figure 3),
indicating higher robustness. These examples demonstrate that statistical significance depends on
the distribution of the longest-surviving patients, with more fragile studies relying on fewer patients
to drive the significance, compared with less fragile studies that are associated with a higher
“reserve” of patients. Similar associations between SIFI as a proportion of the population and P values
are shown in eFigure 2 in the Supplement. To explore the potential association of longer follow-up
periods with the SIFI, we identified trials that published overall survival results for earlier follow-up
periods. We found that the SIFI is stable and displays only a small variation for trials at different
follow-up periods (Table 2),3,4,24,36,37,45,66-70 including studies with median follow-up timemore
than twice as long as in the original publication. Furthermore, we explored the operating
characteristics of the SIFI, including sample size, censoring rate, and effect size (eFigures 3-5 in the
Supplement). Performing simulations using combinations of the parameters resulted in 15 000
synthetic time-to-event data sets. Hazard ratios ranged from0.13 to 1.95, and the percentage of
individuals censored ranged from 17.5% to 50%. The simulated results provide a reference for the
ranges of the SIFI for the various parameters of survival data.
The fragility for survival data can be calculated in various ways. Overall, we calculated 4 versions
of SIFI, which include reassigning patients (flip) or adding patients (clone) to the opposite group
using the best survivors from the experimental group or worst survivors from the control group. A
comparison of the different SIFI approaches is shown for the ITT populations in eFigure 6 in the
Supplement. Compared with the default SIFI (flipping the best survivors to the opposite group) with
amagnitude of 9 (IQR, 5-18) for ITT populations, the 3 alternative versions are associatedwith higher
values in most studies. The SIFI magnitudes are 11 (IQR, 8-18) for flipping the worst survivors to the
opposite group, 17.5 (IQR, 7-38.3) for cloning the best survivors to the opposite group, and 24 (IQR,
16-35) for cloning the worst survivors to the opposite group. These findings suggest that the SIFI
using the version that flips the best survivors to the opposite group is themost sensitive approach for
detecting theminimum changes required to overturn the conclusions.
Discussion
In our study, we found that the statistical significance of a substantial amount of phase 3 trials of ICIs
could be lost or gainedwith a change in assignment of very few of the best surviving patients, often
less than 1% of the respective trial sample size. Although this is an arbitrary number and does not
reflect a random sampling of the patients, it represents a small fraction of the population that can
overturn the statistical conclusions. Also, the change in the number of patients required for fragility
is often smaller than the number of patients censored in the experimental group shortly after
randomization, adding further uncertainties and raising concerns about the statistical outcomes had
these and other patients been assessed to their end point. Eligibility for treatment with ICIs is
assessed by concluding whether results of a trial are positive or negative. Our findings demonstrate
how unstable these conclusions may be, and explain, in part, the widening gap between eligibility
and benefit associated with ICIs.
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The original fragility index has been applied to RCTs in oncology and other areas of
medicine.17,19,71-74However, the original fragility index is based on binary outcomes and the Fisher
exact test, which could bemisleading for time-to-event data, in which the primary interest is the
Figure 2. Survival-Inferred Fragility Index (SIFI) of Overall Survival in Phase 3 Randomized Clinical Trials
SIFI
Cancer type

















































































































Comparison between SIFI levels in different tumor
types among the intention-to-treat populations. Trials
were grouped and colored by tumor type and sorted
by descending order. CRC indicates colorectal cancer;
HCC, hepatocellular carcinoma; HNSCC, head and neck
squamous cell carcinoma; MM,multiple myeloma;
NSCLC, non–small cell lung carcinoma; RCC, renal cell
carcinoma; and SCLC, small cell lung carcinoma.
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Correlation between SIFI and P values for ITT populationsA


















Correlation between SIFI and P values for subgroup populationsB












































































































A, Correlation between SIFI and P values in a logarithmic scale for the intention-to-treat
(ITT) populations. B, Correlation between SIFI and P values in a logarithmic scale for the
subgroup populations. Color bars indicate hazard ratios and circle size represents the
sample size. Correlation was calculated using Pearson correlation coefficient. Horizontal
lines denoting .05 and .001 P value thresholds are shown.
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timing of events.19 Although descriptions of time-to-event fragility exist,18,19 to our knowledge, no
previous peer-reviewed original investigations have estimated time-aware fragility index for clinical
trials, including oncology trials. Also, to our knowledge, no study has evaluated negative fragility
measures for survival analysis.
In general, the P value serves as a measure of the compatibility of collected data with a defined
statistical model. In a testing framework, smaller P values indicate greater evidence against the null
hypothesis—a conjecture of no difference between outcomes of the intervention and control
groups.75Undoubtedly, the P value plays a central role in the clinical testing of new drugs, and since
the 1960s, the FDA has relied on significance testing to establish their effectiveness in the approval
process.76 As such, nowhere is this role more important than in clinical trials, where the smallest
change in the P value can decisively influence the drug approval process and result in trial success or
failure. Consequently, passing the statistical significance threshold has become the ultimate goal,
and unless an analysis is adequately prespecified, most research designs allow enough leeway to
manipulate the results to claim importance.77-80 Therefore, reliance on P values falling to either side
of the significance threshold can result in extreme conclusions and be misleading, especially for a
low threshold such as P < .05. Recently, an influential commentary published in Nature12 has even
called for the abandonment of the conventional threshold for statistical significance, regardless of
the level (eg, P < .05), owing to this imposed dichotomization. However, statistical inferences are
unavoidably dichotomous in many scientific fields. Most decisions in medicine are dichotomous,
such as a new drug will either be approved or not, and will either be prescribed or not.77
This study introduces the SIFI as a novel measure that enables us to estimate the vulnerability
of the statistical conclusions of clinical trials with time-to-event outcomes. This index transforms the
dichotomous conclusion to a discrete variable that provides more perspective regarding the
potential benefit associated with ICIs or any other intervention. The SIFI provides context to the P
value and statistical significance, whichmay not necessarily be intuitive and are often poorly
understood.77 Therefore, the SIFI translates uncertainty to a specified number that represents actual
patients and events and places it on a linear scale that allows for assessment of the robustness of the
results. For example, consider 2 comparable studies with similar P values. Although the SIFI is not a
measure of effect, a trial with a high SIFI with an acceptable association with the sample size and
censoring provides more robustness than a trial with a small SIFI representing a small fraction of the
Table 2. Comparison of SIFI of Overall Survival Calculated for Trials in Different Follow-up Periods





CA184-024 Melanoma 502 201165 39.0 409 5
201524 63.1 427 7
CheckMate-025 RCC 821 201566 22.2 397 8




Melanoma 629 201767 40.2 346 37
201836 51.5 364 38
Monotherapy Melanoma 631 201767 40.2 364 23
201836 51.5 384 23
CheckMate-141 HNSCC 361 201868 17.8 288 4
201837 30.6 321 5
KEYNOTE-006
Every 2 wk Melanoma 557 201569 13.3 196 18
20173 22.5 262 15
Every 3 wk Melanoma 555 201569 13.3 203 12
20173 22.5 260 14
KEYNOTE-045 UC 542 201770 13.6 333 8
201945 28.2 423 9
Abbreviations: HNSCC, head and neck squamous cell
carcinoma; RCC, renal cell carcinoma; SIFI, survival-
inferred fragility index; UC, urothelial carcinoma.
a SIFI associated with the calculated P value (α = .05).
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sample size and censoring. The latter relies on fragile evidence with higher uncertainty regarding the
incompatibility with the null hypothesis. We did not define criteria for fragile vs nonfragile values,
nor do we believe that a measure aimed to address the dichotomization of results by a threshold
should be replaced by another. Perhaps trials involving the addition of a costly and a toxic drug to the
standard treatment with a small effect size would require a higher level of robustness than trials
comparing 2 drugs with similar overall properties. In contrast, concluding that statistically significant
results show no real association when the fragility measure is very low is discouraged; it is equally
inaccurate to claim that nonsignificant results with very small negative fragility point to an important
signal. However, the SIFI allows for putting these 2 scenarios in context, expressing uncertainty and
suggesting that the interpretation of their importance should be similar or, de facto, the same. In
both cases, and especially for negative fragility measures, small values indicate that the true
underlying effects either are negligible or lack statistical power. Nevertheless, considerations such as
study design, data quality, comprehension of the underlying mechanisms, and other factors may
often havemore importance than statistical findings12 such as P values or fragility indices.
The default solution for improving the confidence level would bemaking the barrier more
demanding; however, this is a suboptimal option because the chance for false-negative results
increases accordingly, and it still fails to address the vulnerability of the statistics. Nevertheless,
fragility corresponding to one threshold is not comparable with another, and it is reasonable to
expect lower fragility measures for lower P value thresholds, as they are interrelated. Hence, the
approach encourages using lower significance thresholds. A trial not meeting a low prespecified
significance threshold (eg, P < .0001), with a small negative SIFI (eg, −2), may provide higher
confidence in the validity of the results compared with a trial that meets a higher threshold (eg,
P < .05) but has a low positive SIFI (eg, 2). The SIFI relative to sample size can be useful to estimate
the robustness of the results, but it could be misleading for small sample sizes. Although SIFI less
than 1% inmany RCTs could suggest extreme fragility, small trials with less than 100 patients cannot
achieve a SIFI of less than 1%, even when the results are certainly less robust. Therefore, the SIFI
relative to sample size, especially for small trials, should not be interpreted alone andmust be
accompanied by the SIFI.
Limitations
Several limitations of the study should be recognized. We did not address prespecified P value
thresholds, which were allocated and controlled differently in every trial and are often much lower
than .05. Instead, we used the standard α level of .05 as a common reference; therefore, some trials
did not meet the prespecified threshold but resulted in a positive SIFI. Although not a strict rule by
the FDA, the standard 2-trial α level is .05 but is smaller for approval based on a single trial.76 The
analysis of overall survival was based on an unstratified log-rank test at a 2-sided significance level as
a uniform statistical test for all trials; however, studies have analyzed the data differently (eg,
stratified or weighted log-rank test). Therefore, small differences exist between the published P value
and the calculated P value. Furthermore, we found a small discrepancy in the numbers of patients at
risk published in the original publications and the reproduced curves. For 19 of the 49 populations in
the trials (39%), there was no discrepancy between the published and estimated number at risk at
any time point. In the time points for which discrepancy existed, we found the difference to be small,
with a median of 1 patient (IQR, 1-2).
The SIFI can be calculated in various ways. Our comparison of different implementations of the
SIFI demonstrates that reassigning or adding the best survivors to the opposite group provides lower
fragility estimates compared with the worst survivors, for most trials. This finding indicates that the
longest-surviving patients can tilt the balance between the groups more strongly compared with the
shortest-surviving patients. The association of the longest survivors with the survival curves is
potentially unlimited, as they are constrained only by the follow-up time, whereas the shortest-
surviving patients cannot have an event before time zero. By both removing a long-time survivor
from one group and adding them to the other group, the total number of patients required to pass
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the significance threshold is reduced compared with other techniques. This approach coincides with
the essence of fragility—identifying theminimum required changes to overturn the conclusions.
Furthermore, we aimed to define a simple and intuitive method that can be recreated using existing
routines, is quantifiable in all conditions, and is applicable to real-world practice in which patients are
randomly assigned from a pool of eligible patients. Although random variations alone can lead to
large disparities in P values, the calculation of the SIFI is not based on random variations in the
assignment of patients but on the reassignment of patients at the extreme ends of the scale.
However, the random allocation of patients can lead to different proportions of the best (or worst)
survivors in the groups, which may impact the outcomes. Therefore, the SIFI serves as a simple and
conservative approach to reflect the fragility of the statistics. Alternatively, the mean or median
survival time can be exploited in different ways to quantify the fragility18,19; however, this approach
can underestimate the fragility if the few patients who causemost of the difference are not captured.
Conclusions
The results of this study suggest that many phase 3 RCTs evaluating ICI therapies are fragile and
challenge the confidence in rejecting or concluding superiority for these drugs compared with
standard treatments. Low fragility levels express uncertainty when there is no appreciable difference
between the interpretative significance of data. In contrast, high fragility levels can provide
robustness and aid in binary decision-making, especially for treatments associatedwith high cost and
toxic effects that require strong support. Interpretation of any outcome is farmore complicated than
just significance testing, and the SIFI as a statistical and communication tool may serve as a better
starting point for discerning between science and fiction.
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